Long non‑coding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miR‑135b‑5p to target KLF9

Wu,Linlin; Xia,Liang; Jiang,Huimin; Hu,Yue; Li,Lingling; Xu,Li; Xia,Ruixiang

doi:10.3892/mmr.2021.12288

Long non‑coding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miR‑135b‑5p to target KLF9

Authors:
- Linlin Wu
- Liang Xia
- Huimin Jiang
- Yue Hu
- Lingling Li
- Li Xu
- Ruixiang Xia
View Affiliations

Affiliations: Department of Hematology, Anhui No. 2 Provincial People's Hospital, Hefei, Anhui 230041, P.R. China, Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: July 13, 2021 https://doi.org/10.3892/mmr.2021.12288
Article Number: 649

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple myeloma (MM) is a malignancy of plasma cells that leads to marrow failure and bone lesions. Numerous studies have verified the link between long non‑coding RNAs (lncRNAs) and MM. The present study aimed to examine the role and underlying mechanism of differentiation antagonizing non‑protein coding RNA (DANCR) in MM cells. The relative expression levels of DANCR, microRNA (miR)‑135b‑5p and Krüppel‑like factor 9 (KLF9) were examined using reverse transcription‑quantitative PCR. Cell viability was assessed using the MTT assay, while relative cell migration and invasion were evaluated using Transwell assays. Moreover, the dual‑luciferase reporter assay was used to examine the interplay between DANCR, miR‑135b‑5p and KLF9. Western blotting was performed to determine the expression level of KLF9. It was found that lncRNA DANCR and KLF9 were downregulated, while miR‑135b‑5p was upregulated in the serum of patients with MM and in MM cells compared with the controls. Overexpressing DANCR or knocking down miR‑135b‑5p reduced the viability of the MM cells, as well as restrained MM cells from migrating and invading. Furthermore, DANCR directly targeted miR‑135b‑5p and was negatively correlated with miR‑135b‑5p. It was also found that KLF9 was targeted by miR‑135b‑5p and was inversely correlated with miR‑135b‑5p expression. The impact of lncRNA DANCR‑mediated suppression on cell viability, invasion and migration was partially abolished by short hairpin RNA KLF9 or miR‑135b‑5p mimics transfection in MM cells. Thus, it was suggested that lncRNA DANCR repressed the viability, migration and invasion of MM cells by sponging miR‑135b‑5p to target KLF9.

View Figures

View References

1	Harding T, Baughn L, Kumar S and Van Ness B: The future of myeloma precision medicine: Integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia. 33:863–883. 2019. View Article : Google Scholar : PubMed/NCBI
2	Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F and Anderson KC: Multiple myeloma. Nat Rev Dis Primers. 3:170462017. View Article : Google Scholar : PubMed/NCBI
3	Laubach J, Richardson P and Anderson K: Multiple myeloma. Annu Rev Med. 62:249–264. 2011. View Article : Google Scholar : PubMed/NCBI
4	Röllig C, Knop S and Bornhäuser M: Multiple myeloma. Lancet. 385:2197–2208. 2015. View Article : Google Scholar
5	Zhou W, Yang Y, Gu Z, Wang H, Xia J, Wu X, Zhan X, Levasseur D, Zhou Y, Janz S, et al: ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia. 28:1155–1158. 2014. View Article : Google Scholar : PubMed/NCBI
6	Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, et al: International myeloma working group molecular classification of multiple myeloma: Spotlight review. Leukemia. 23:2210–2221. 2009. View Article : Google Scholar : PubMed/NCBI
7	Detappe A, Bustoros M, Mouhieddine TH and Ghoroghchian PP: Advancements in nanomedicine for multiple myeloma. Trends Mol Med. 24:560–574. 2018. View Article : Google Scholar : PubMed/NCBI
8	Mateos MV, Ludwig H, Bazarbachi A, Beksac M, Bladé J, Boccadoro M, Cavo M, Delforge M, Dimopoulos MA, Facon T, et al: Insights on multiple myeloma treatment strategies. Hemasphere. 3:e1632018. View Article : Google Scholar : PubMed/NCBI
9	Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar : PubMed/NCBI
10	Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, et al: Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 458:223–227. 2009. View Article : Google Scholar : PubMed/NCBI
11	Gibb EA, Brown CJ and Lam WL: The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 10:382011. View Article : Google Scholar : PubMed/NCBI
12	Liu N, Feng S, Li H, Chen X, Bai S and Liu Y: Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and glycolysis of multiple myeloma via miR-1271-5p/SOX13 axis. J Cancer Res Clin Oncol. 146:367–379. 2020. View Article : Google Scholar : PubMed/NCBI
13	Wang Y, Wang H, Ruan J, Zheng W, Yang Z and Pan W: Long non-coding RNA OIP5-AS1 suppresses multiple myeloma progression by sponging miR-27a-3p to activate TSC1 expression. Cancer Cell Int. 20:1552020. View Article : Google Scholar : PubMed/NCBI
14	Shen Y, Feng Y, Chen H, Huang L, Wang F, Bai J, Yang Y, Wang J, Zhao W, Jia Y, et al: Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma. Life Sci. 196:133–142. 2018. View Article : Google Scholar : PubMed/NCBI
15	Hu AX, Huang ZY, Zhang L and Shen J: Potential prognostic long non-coding RNA identification and their validation in predicting survival of patients with multiple myeloma. Tumour Biol. 39:10104283176945632017. View Article : Google Scholar : PubMed/NCBI
16	Liang H, Zhang C, Guan H, Liu J and Cui Y: LncRNA DANCR promotes cervical cancer progression by upregulating ROCK1 via sponging miR-335-5p. J Cell Physiol. 234:7266–7278. 2019. View Article : Google Scholar : PubMed/NCBI
17	Pan Z, Wu C, Li Y, Li H, An Y, Wang G, Dai J and Wang Q: LncRNA DANCR silence inhibits SOX5-medicated progression and autophagy in osteosarcoma via regulating miR-216a-5p. Biomed Pharmacother. 122:1097072020. View Article : Google Scholar : PubMed/NCBI
18	Allegra A, Mania M, D'Ascola A, Oteri G, Siniscalchi EN, Avenoso A, Innao V, Scuruchi M, Allegra AG, Musolino C and Campo S: Altered long noncoding RNA expression profile in multiple myeloma patients with bisphosphonate-induced osteonecrosis of the Jaw. Biomed Res Int. 2020:98798762020. View Article : Google Scholar : PubMed/NCBI
19	Zhang G, Pian C, Chen Z, Zhang J, Xu M, Zhang L and Chen Y: Identification of cancer-related miRNA-lncRNA biomarkers using a basic miRNA-lncRNA network. PLoS One. 13:e01966812018. View Article : Google Scholar : PubMed/NCBI
20	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
21	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
22	Handa H, Murakami Y, Ishihara R, Kimura-Masuda K and Masuda Y: The role and function of microRNA in the pathogenesis of multiple myeloma. Cancers (Basel). 11:17382019. View Article : Google Scholar : PubMed/NCBI
23	Liu H, Wu Y, Wang S, Jiang J, Zhang C, Jiang Y, Wang X, Hong L and Huang H: Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p. BMC Cancer. 19:9372019. View Article : Google Scholar : PubMed/NCBI
24	Kong Y, Hu L, Lu K, Wang Y, Xie Y, Gao L, Yang G, Xie B, He W, Chen G, et al: Ferroportin downregulation promotes cell proliferation by modulating the Nrf2-miR-17-5p axis in multiple myeloma. Cell Death Dis. 10:6242019. View Article : Google Scholar : PubMed/NCBI
25	Hao M, Zang M, Zhao L, Deng S, Xu Y, Qi F, An G, Qin Y, Sui W, Li F, et al: Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget. 7:19589–19600. 2016. View Article : Google Scholar : PubMed/NCBI
26	Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K and Van Riet I: Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. PLoS One. 8:e797522013. View Article : Google Scholar : PubMed/NCBI
27	Sweet DR, Fan L and Jain MK: Taking KLF9 to ‘Cort’ for crimes against metabolism. J Clin Invest. 129:2178–2180. 2019. View Article : Google Scholar : PubMed/NCBI
28	Imataka H, Sogawa K, Yasumoto K, Kikuchi Y, Sasano K, Kobayashi A, Hayami M and Fujii-Kuriyama Y: Two regulatory proteins that bind to the basic transcription element (BTE), a GC box sequence in the promoter region of the rat P-4501A1 gene. EMBO J. 11:3663–3671. 1992. View Article : Google Scholar : PubMed/NCBI
29	Zhong Z, Zhou F, Wang D, Wu M, Zhou W, Zou Y, Li J, Wu L and Yin X: Expression of KLF9 in pancreatic cancer and its effects on the invasion, migration, apoptosis, cell cycle distribution, and proliferation of pancreatic cancer cell lines. Oncol Rep. 40:3852–3860. 2018.PubMed/NCBI
30	Kong YJ, Tan XX, Zhang Y, He QJ, Zhao L and Meng Q: MiR-141 promotes cell proliferation and invasion in non-small cell lung cancer by targeting KLF9. Eur Rev Med Pharmacol Sci. 23:10370–10378. 2019.PubMed/NCBI
31	Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, et al: KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood. 119:1450–1458. 2012. View Article : Google Scholar : PubMed/NCBI
32	International Myeloma Working Group, : Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the international myeloma working group. Br J Haematol. 121:749–757. 2003. View Article : Google Scholar : PubMed/NCBI
33	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
34	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar : PubMed/NCBI
35	De Beule N, Menu E, Bertrand MJM, Favreau M, De Bruyne E, Maes K, De Veirman K, Radwanska M, Samali A, Magez S, et al: Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells. Oncotarget. 8:52016–52025. 2017. View Article : Google Scholar : PubMed/NCBI
36	Chen Z, Chen X, Xie R, Huang M, Dong W, Han J, Zhang J, Zhou Q, Li H, Huang J and Lin T: DANCR promotes metastasis and proliferation in bladder cancer cells by enhancing IL-11-STAT3 signaling and CCND1 expression. Mol Ther. 27:326–341. 2019. View Article : Google Scholar : PubMed/NCBI
37	Bai Y, Zhang G, Chu H, Li P and Li J: The positive feedback loop of lncRNA DANCR/miR-138/Sox4 facilitates malignancy in non-small cell lung cancer. Am J Cancer Res. 9:270–284. 2019.PubMed/NCBI
38	Jia J, Li F, Tang XS, Xu S, Gao Y, Shi Q, Guo W, Wang X, He D and Guo P: Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3. Oncotarget. 7:37868–37881. 2016. View Article : Google Scholar : PubMed/NCBI
39	Lu QC, Rui ZH, Guo ZL, Xie W, Shan S and Ren T: LncRNA-DANCR contributes to lung adenocarcinoma progression by sponging miR-496 to modulate mTOR expression. J Cell Mol Med. 22:1527–1537. 2018. View Article : Google Scholar : PubMed/NCBI
40	Chen Z, Gao Y, Gao S, Song D and Feng Y: MiR-135b-5p promotes viability, proliferation, migration and invasion of gastric cancer cells by targeting Krüppel-like factor 4 (KLF4). Arch Med Sci. 16:167–176. 2019. View Article : Google Scholar : PubMed/NCBI
41	Zhang Z, Che X, Yang N, Bai Z, Wu Y, Zhao L and Pei H: miR-135b-5p Promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2. Biomed Pharmacother. 96:1341–1348. 2017. View Article : Google Scholar : PubMed/NCBI
42	Chen N, Yin D, Lun B and Guo X: LncRNA GAS8-AS1 suppresses papillary thyroid carcinoma cell growth through the miR-135b-5p/CCND2 axis. Biosci Rep. 39:BSR201814402019. View Article : Google Scholar : PubMed/NCBI
43	Zhao CC, Jiao Y, Zhang YY, Ning J, Zhang YR, Xu J, Wei W and Kang-Sheng G: Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt/β-catenin pathway by sponging miR-135b-5p to elevate expression of APC. Cell Death Dis. 10:2522019. View Article : Google Scholar : PubMed/NCBI
44	Zhang Y, Zhang Z, Yi Y, Wang Y and Fu J: CircNOL10 acts as a sponge of miR-135a/b-5p in suppressing colorectal cancer progression via regulating KLF9. Onco Targets Ther. 13:5165–5176. 2020. View Article : Google Scholar : PubMed/NCBI